QuartzBio’s suite of end-to-end SaaS options gives pharmaceutical and biotech shoppers with a completely related information ecosystem linking pattern, biomarker, and medical information to enhance collaboration, planning and R&D productiveness.
FREDERICK, Md., Jan. 24, 2023 /PRNewswire/ — Precision for Medication, the primary international, precision drugs medical analysis companies group, as we speak introduced the strategic acquisition of SolveBio by QuartzBio.
SolveBio’s clever applied sciences and enterprise information administration platform has built-in into QuartzBio’s suite of SaaS options, offering a single, scalable resolution supporting medical pattern stock administration and biomarker information administration for the biotech and pharmaceutical sectors.
The mixed choices beneath QuartzBio present scientific and operations groups in drug improvement with an agile, user-friendly information administration platform that permits enterprise-level visibility throughout the lifecycle of their pattern and biomarker information. Leveraging this expanded enterprise suite of options, scientists in translational analysis and medical operations can extra simply collaborate throughout capabilities, analyze and report on key datasets, and generate insights.
“We’re excited to have SolveBio becoming a member of forces with QuartzBio,” says Scott Marshall, Ph.D., Common Supervisor of QuartzBio. “As our business continues to innovate, it’s crucial that we proceed to advance our portfolio of enterprise options to allow scale and connectivity in help of our final objective – delivering therapies to sufferers. Integrating SolveBio’s expertise with QuartzBio’s current portfolio helps us accomplish that.”
QuartzBio’s totally related, end-to-end SaaS options are engineered to allow seamless monitoring and monitoring of medical pattern standing, knowledgeable consent kind (ICF) monitoring/codification, and administration of biomarker information throughout the enterprise, leading to a unified resolution for the administration and supply of each samples and their associated biomarker information. The platform is used to generate scientific and operational insights, whereas research are in progress, after research are full, and throughout a number of medical applications.
Combining the QuartzBio and SolveBio groups’ experience and scale, QuartzBio can now higher help shoppers’ strategic objectives and day-to-day productiveness by serving to medical and translational groups:
- Save time with expertise that maps information as-is, from any supply, utilizing the format offered by the lab, vendor, or different supply techniques with no adjustments required—rising flexibility and dashing deployment.
- Achieve visibility into pattern standing with digital Pattern Stock Administration, a single supply of fact linking samples and derivatives with medical information, knowledgeable consent, delivery standing, and extra – throughout a number of websites, labs, and repositories.
- Improve effectivity and reporting accuracy with enterprise-wide Biomarker Knowledge Administration, as all sample-related information shall be centralized and harmonized in a unified information platform, thus eliminating the necessity to seek for information in a number of storage places.
- Consolidate visibility to saved samples from all research (lively and inactive) with digital Biorepository, throughout geographies, biorepositories, and central labs (long-term storage) to facilitate planning for future information era.
- Collaborate and join by leveraging biomarker-specific visualizations (e.g., genomic and circulation information modules), shareable dashboards, inside and exterior notifications, and utility programming interfaces (APIs)/connectors that permit the QuartzBio options to empower choice making within the context of a posh information ecosystem.
“We’re very excited to hitch Precision for Medication and change into part of QuartzBio,” says Mark Kaganovich, SolveBio’s Founder and CEO. “It is a large alternative to proceed enhancing our providing to our clients.” “QuartzBio’s acquisition of SolveBio is a serious step ahead in our objective to unravel biomarker information administration for the pharmaceutical and biotech business,” says David Caplan, SolveBio’s Co-Founder and CTO. “By becoming a member of QuartzBio’s superb staff, we can present the great resolution our shoppers must get precision therapies out to sufferers quicker. We’re honored to be part of this journey.”
About Precision for Medication
Precision for Medication is the primary biomarker-driven medical analysis companies group supporting life sciences firms in using biomarkers important to concentrating on affected person therapies extra exactly and successfully. Precision applies novel biomarker approaches to medical analysis that combine medical trial design and execution with deep scientific data, laboratory experience and superior information sciences. This convergence of trials, labs and information sciences is driving quicker medical improvement and approval. Precision for Medication is a part of Precision Medication Group, with 3,200 folks in 40 places within the U.S., Canada, Europe and Australia. For extra data, go to PrecisionForMedicine.com.
About QuartzBio
QuartzBio helps overcome the info chaos inherent in trendy drug improvement. We serve medical operations and translational analysis groups in oncology, autoimmune, CNS and different biomarker-rich therapeutic areas, whose progress hinges on navigating and connecting a posh information ecosystem. Our suite of totally related, end-to-end SaaS options is engineered particularly to handle the challenges of each pattern information and biomarker information administration – offering a single, scalable information platform resolution to the biotech and pharma sectors. For extra data, go to Quartzbio.com.
About SolveBio
SolveBio is an business chief in superior precision drugs information analytics. Its expertise platform allows biopharma clients to decrease trial threat, create simpler therapeutics, and compress the time scale of medical improvement. The core of SolveBio’s platform is expertise to attach genomic information that comes from a quickly compounding advanced panorama of distributors, research, and sufferers.
Media Contact:
Ann Smith, Precision Medication Group Media Relations
201-680-9447
asmith@coynepr.com
View unique content material to obtain multimedia:https://www.prnewswire.com/news-releases/quartzbio-a-part-of-precision-for-medicine-acquires-solvebio-and-expands-software-as-a-service-saas-data-management-solutions-for-clinical-research–development-rd-301728685.html
SOURCE Precision for Medication, Inc.
